JAZZ Venture Partners

Investment decisions are led by co-founders and managing partners John Spinale and Zack Lynch. Spinale brings operating experience scaling consumer platforms, including as a former executive at Disney's Club Penguin. Lynch authored The Neuro Revolution (2009) and founded the Neurotechnology Industry Organization, bringing the neurotech thesis depth to the partnership.

The firm defines human augmentation as technology that measurably improves human cognition, physical performance, recovery, or mental health through a direct interface with brain function or neural pathways. This spans neurostimulation devices, digital therapeutics for conditions like depression and chronic pain, sleep optimization platforms, and cognitive training software. The common requirement is a mechanistic link to neuroscience — pure wellness apps or fitness trackers without a clinical or neural evidence basis fall outside the thesis.

No. While digital health and digital therapeutics are core, JAZZ also invests in consumer performance platforms, professional athlete training tools, and wellness technology. The unifying thread is neuroscience and human performance, not a specific regulatory category. Portfolio company Aura Health, for instance, is a consumer meditation and sleep app, while Halo Neuroscience (acquired) sold a neurostimulation headset to both elite athletes and general consumers.

JAZZ invests from seed through growth stages, with a preference for leading or co-leading rounds. Early checks target companies translating lab-stage neuroscience into a commercial prototype, while growth investments back companies with clinical validation and early revenue that are scaling toward FDA clearance or mass consumer adoption.

Most digital health firms evaluate companies through a clinical or payer-economics lens. JAZZ adds a mandatory neuroscience screen — the firm requires that a portfolio company's mechanism of action be traceable to a specific neural or brain-function pathway. This screens out many general telehealth and EHR companies while pulling in non-traditional health deals like neuro-gaming and elite sports performance.